Pentwater Capital Management’s Acceleron Pharma XLRN Stock Holding History

Pentwater Capital Management’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,050,000	Closed	-$181M	–	285
2021 Q3	$181M	Buy	+1,050,000	New	+$137M	1.84%	16
2015 Q4	–	Sell	-96,771	Closed	-$2.41M	–	144
2015 Q3	$2.41M	Sell	96,771 -115,229	-54%	-$3.46M	0.02%	106
2015 Q2	$6.71M	Buy	212,000 +130,000	+159%	+$4.2M	0.04%	112
2015 Q1	$3.12M	Buy	82,000 +2,000	+3%	+$79.5K	0.02%	127
2014 Q4	$3.12M	Buy	+80,000	New	+$2.79M	0.02%	117

Pentwater Capital Management's XLRN Position: Q4 2021 in Review

Pentwater Capital Management sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 1,050,000 shares — an estimated $181M sold.

Pentwater Capital Management first reported a position in XLRN in Q4 2014 and held it in 5 quarters. The position peaked at $181M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

Pentwater Capital Management reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
Pentwater Capital Management sold 1,050,000 Acceleron Pharma shares in Q4 2021, an estimated $181M.
Pentwater Capital Management first reported a position in Acceleron Pharma in Q4 2014 and held it in 5 quarters.
Pentwater Capital Management's Acceleron Pharma position peaked at $181M in Q3 2021.
1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on Pentwater Capital Management's 13F filing for Q4 2021, filed 11 Feb 2022.